Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

66.92EUR
9:53am EDT
Change (% chg)

€-1.29 (-1.89%)
Prev Close
€68.21
Open
€66.89
Day's High
€67.16
Day's Low
€65.84
Volume
437,829
Avg. Vol
790,778
52-wk High
€82.32
52-wk Low
€50.75

FMEG.DE

Chart for FMEG.DE

About

Fresenius Medical Care AG & Co. KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of... (more)

Overall

Beta: 0.32
Market Cap(Mil.): €21,294.94
Shares Outstanding(Mil.): 312.20
Dividend: 0.78
Yield (%): 1.14

Financials

  FMEG.DE Industry Sector
P/E (TTM): 23.49 29.66 36.13
EPS (TTM): 2.90 -- --
ROI: 6.69 8.08 14.83
ROE: 11.72 21.88 15.69
Search Stocks

BRIEF-Fresenius Medical to sell Venezuela dialysis services unit

* Says plan to sell Venezuela dialysis service business, to incur $30 million loss Further company coverage:

30 Jul 2015

Fresenius raises 2015 profit guidance on generic infusion drugs

FRANKFURT - German healthcare group Fresenius SE on Wednesday lifted its full-year earnings target for the second time as its rivals in the U.S. generic infusion drug market struggled with longer-than-expected production outages.

29 Jul 2015

UPDATE 1-Fresenius raises 2015 profit guidance on generic infusion drugs

* Fresenius boosted by drug launches, rivals' production blunders

29 Jul 2015

BRIEF-Fresenius Medical Care confirms guidance for 2015

* Says q2 dialysis product revenue decreased by 4% on year to $854 million mainly due to negative currency developments

29 Jul 2015

BRIEF-FMC sees care coordination adding to earnings from 2016

* Says expects care coordination businesses to start adding to earnings from 2016

19 May 2015

Fresenius ups profit forecast on higher infusion drug sales

FRANKFURT - German healthcare group Fresenius SE lifted its full-year earnings forecast as its rivals in the U.S. generic infusion drug market grappled with supply shortages longer than expected.

29 Apr 2015

UPDATE 1-Fresenius ups profit forecast on higher infusion drug sales

* Expects adj net income growth of 13-16 pct, before forex effects

29 Apr 2015

FMC confirms outlook as quarterly profit in line

FRANKFURT, April 29 - Kidney dialysis specialist Fresenius Medical Care (FMC) reported a 2 percent rise in quarterly net profit, meeting expectations, and confirmed its guidance for 2015.

29 Apr 2015

Fitch Revises Fresenius' Outlook to Stable; Affirms at 'BB+'

(The following statement was released by the rating agency) LONDON, March 19 (Fitch) Fitch Ratings has revised Fresenius Medical Care AG & Co. KGaA's (FMC) and Fresenius SE & Co. KGaA's (FSE, consolidated 'Fresenius') Outlook to Stable from Positive. Its Long- and Short-term Issuer Default Ratings (IDRs) have been affirmed at 'BB+' and 'B', respectively. Please see below for a detailed list of rating actions. Although Fresenius' business risk profile has improved, with its scale, profitabil

19 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks